



RECEIVED

SEP 04 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING  
37 C.F.R. §1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: U.S. Patent And Trademark Office, Box Sequence Listing, P.O. Box 2327, Arlington, VA 22202, on the date below:

August 26, 2002  
Date of Deposit

Steven L. Highlander

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
Zhijian J. CHEN *et al.*

Serial No.: 10/076,918

Filed: October 11, 2001

For: TRAF6-REGULATED IKK  
ACTIVATORS (TRIKA1 AND TRIKA2)  
AND THEIR USE AS ANTI-  
INFLAMMATORY TARGETS

Group Art Unit: 1641

Examiner: Unknown

Atty. Dkt. No.: UTSD:857US/SLH

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID  
SEQUENCE DISCLOSURES DATED JUNE 26, 2002**

U.S. Patent and Trademark Office  
Box Sequence, P.O. Box 2327  
Arlington, VA 22202

Commissioner:

This paper is submitted in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated June 26, 2002 for which the due date is August 26, 2002.


It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/10107423/SLH.

**RESPONSE TO NOTICE**

Submitted herewith is a Statement As Required Under 37 C.F.R. § 1.821(f); paper copy of sequence listing and computer readable form (CRF) which comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures.

Applicants believe that the attached documents fully responds to the Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures for this application.

Respectfully submitted,



Steven L. Highlander  
Reg. No. 37,642  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201  
(512) 536-4598 (facsimile)

Date: August 26, 2002



UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Page 1 of 2

SEP 04 2002

TECH CENTER 1600/2900  
COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/076,918	10/11/2001	Zhijian J. Chen	UTSD:857US/SLH

Steven L. Highlander  
Fulbright & Jaworski L.L.P.  
Suite 2400  
600 Congress Avenue  
Austin, TX 78701



CONFIRMATION NO. 8460

FORMALITIES LETTER



\*OC000000008354328\*

Date Mailed: 06/26/2002

- The provisional application cover sheet under 37 CFR 1.51(c)(1), which may be an application data sheet (37 CFR 1.76), is required identifying:
  - either city and state or city and foreign country of the residence of each inventor.

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

**For questions regarding compliance to these requirements, please contact:**

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

**For questions regarding compliance to these requirements, please contact:**

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

---

*A copy of this notice MUST be returned with the reply.*

  
\_\_\_\_\_  
Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

COPY OF PAPERS  
ORIGINALLY FILED



**FULBRIGHT & JAWORSKI L.L.P.**

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
WWW.FULBRIGHT.COM


STEVEN LEE HIGHLANDER  
PARTNER  
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3184  
TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

RECEIVED 1641  
Box 500  
SEP 04 2002

TECH CENTER 1600/2900

August 26, 2002

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202, on the date below:	
August 26, 2002 Date	 Steven L. Highlander

U.S. Patent and Trademark Office  
Box Sequence, P.O. Box 2327  
Arlington, VA 22202

Re: *U.S. Patent Application Entitled: TRAF6-REGULATED IKK ACTIVATORS (TRIKA1 AND TRIKA2) AND THEIR USE AS ANTI-INFLAMMATORY TARGETS - Zhijian J. Chen and Lin Deng*  
Our Ref. No. UTSD:857US; Matter No.: 10107423

Commissioner:

Enclosed for filing in the above-referenced patent application is:

- (1) Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
- (2) Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Dated June 26, 2002;
- (3) Statement as Required Under 37 C.F.R. § 1.821(f); Paper Copy of Sequence Listing; Computer Readable Form (CRF); and
- (4) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.


25201984.1

AUSTIN • DALLAS • HONG KONG • HOUSTON • LONDON • LOS ANGELES • MINNEAPOLIS • MUNICH • NEW YORK • SAN ANTONIO • WASHINGTON DC

Commissioner For Patents  
August 26, 2002  
Page 2

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/10107423/SLH.

Respectfully submitted,



Steven L. Highlander  
Reg. No. 37,642

SLH/cpj

Encl.: